ABSTRACT NUMBER: ESOC2026A507 DETERMINANTS AND CLINICAL IMPACT OF ANTICOAGULATION REVERSAL IN ORAL ANTICOAGULANT–RELATED INTRACEREBRAL HEMORRHAGE

Abstract Background and aims Oral anticoagulant (OAC)–related intracerebral hemorrhage (ICH) carries high mortality. Despite guideline recommendations, anticoagulation reversal is inconsistently used, particularly in severe presentations. We aimed to identify determinants of reversal administration and its association with mortality in real-world practice. Methods We analyzed data from the prospective, multicenter ARICH registry including consecutive OAC-related ICH patients admitted to 18 Spanish stroke centers (2019–2024). Outcomes included reversal administration (primary) and 24-hour and 90-day mortality. Hierarchical mixed-effects regression models with hospital-level random intercepts were used. Post-hoc analyses evaluated mortality in patients with ICH volume >60 mL and/or GCS ≤5, commonly excluded from RCTs. Results Among 891 patients (mean age 79.0±9.3 years, 541 [60.7%] male), 678 (76.1%) received reversal. Independent determinants included baseline mRS (aOR 0.84, 95% CI 0.71-0.99), GCS (aOR 1.24, 95% CI 1.13-1.36), ICH volume (per 10-mL increase, aOR 0.86, 95% CI 0.80-0.93), and time since last DOAC dose (per 60-minute increase, aOR 0.94, 95% CI 0.92-0.97). Overall 24-hour mortality was 159/889 (17.9%) and 90-day mortality was 429/887 (48.6%). Reversal was independently associated with lower 24-hour (aOR 0.32, 95% CI 0.18-0.56) and 90-day (aOR 0.59, 95% CI 0.35-0.99) mortality, and with improved outcomes across clinical severity strata: lower 24-hour mortality (Figure 1A) and higher 90-day survival (Figure 1B) (adjusted log-rank P<0.05 for all pairwise comparisons). Conclusions In real-world practice, anticoagulation reversal is influenced by perceived prognosis and is independently associated with lower 24-hour and 90-day mortality, including among patients with severe ICH presentations. Conflict of interest David Rodriguez-Luna: nothing to disclose. Olalla Pancorbo: nothing to disclose. Ana Núñez: nothing to disclose. Renato Simonetti: nothing to disclose. Laura Sánchez Cirera: nothing to disclose. Marta Serrano Ponz: nothing to disclose. Rocío Vera Lechuga: nothing to disclose. Cristina Pérez: nothing to disclose. Luis Prats-Sanchez: nothing to disclose. Carlos A. Molina: nothing to disclose. Figure 1 - belongs to Results

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.327
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A507 DETERMINANTS AND CLINICAL IMPACT OF ANTICOAGULATION REVERSAL IN ORAL ANTICOAGULANT–RELATED INTRACEREBRAL HEMORRHAGE

Renato Simonetti, Ana Nuñez Guillen, Olalla Pancorbo, Luís Prats‐Sánchez et al.
European Stroke Journal
Intracerebral and Subarachnoid Hemorrhage Research
article

ABSTRACT NUMBER: ESOC2026A507 DETERMINANTS AND CLINICAL IMPACT OF ANTICOAGULATION REVERSAL IN ORAL ANTICOAGULANT–RELATED INTRACEREBRAL HEMORRHAGE

Renato Simonetti, Ana Nuñez Guillen, Olalla Pancorbo, Luís Prats‐Sánchez, Marta Serrano, Rocío Vera, Laura Sanchez Cirera, Carlos A Molina, Cristina Perez Lazaro, David Rodriguez-Luna
article en

Abstract

Abstract Background and aims Oral anticoagulant (OAC)–related intracerebral hemorrhage (ICH) carries high mortality. Despite guideline recommendations, anticoagulation reversal is inconsistently used, particularly in severe presentations. We aimed to identify determinants of reversal administration and its association with mortality in real-world practice. Methods We analyzed data from the prospective, multicenter ARICH registry including consecutive OAC-related ICH patients admitted to 18 Spanish stroke centers (2019–2024). Outcomes included reversal administration (primary) and 24-hour and 90-day mortality. Hierarchical mixed-effects regression models with hospital-level random intercepts were used. Post-hoc analyses evaluated mortality in patients with ICH volume >60 mL and/or GCS ≤5, commonly excluded from RCTs. Results Among 891 patients (mean age 79.0±9.3 years, 541 [60.7%] male), 678 (76.1%) received reversal. Independent determinants included baseline mRS (aOR 0.84, 95% CI 0.71-0.99), GCS (aOR 1.24, 95% CI 1.13-1.36), ICH volume (per 10-mL increase, aOR 0.86, 95% CI 0.80-0.93), and time since last DOAC dose (per 60-minute increase, aOR 0.94, 95% CI 0.92-0.97). Overall 24-hour mortality was 159/889 (17.9%) and 90-day mortality was 429/887 (48.6%). Reversal was independently associated with lower 24-hour (aOR 0.32, 95% CI 0.18-0.56) and 90-day (aOR 0.59, 95% CI 0.35-0.99) mortality, and with improved outcomes across clinical severity strata: lower 24-hour mortality (Figure 1A) and higher 90-day survival (Figure 1B) (adjusted log-rank P<0.05 for all pairwise comparisons). Conclusions In real-world practice, anticoagulation reversal is influenced by perceived prognosis and is independently associated with lower 24-hour and 90-day mortality, including among patients with severe ICH presentations. Conflict of interest David Rodriguez-Luna: nothing to disclose. Olalla Pancorbo: nothing to disclose. Ana Núñez: nothing to disclose. Renato Simonetti: nothing to disclose. Laura Sánchez Cirera: nothing to disclose. Marta Serrano Ponz: nothing to disclose. Rocío Vera Lechuga: nothing to disclose. Cristina Pérez: nothing to disclose. Luis Prats-Sanchez: nothing to disclose. Carlos A. Molina: nothing to disclose. Figure 1 - belongs to Results

European Stroke JournalVol. 11(Supplement_1)
Hebron University (PS), Instituto Cajal (ES), Universitat de Girona (ES), Hospital de Sant Pau (ES), Bellvitge University Hospital (ES), Vall d'Hebron Institut de Recerca (ES), Institut d'Investigació Biomèdica de Girona (ES), Hospital Universitario Miguel Servet (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Clínico Universitario Lozano Blesa (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), Hospital Universitario Ramón y Cajal (ES)
Good health and well-being
Openalex Percentile: Top 8%
Intracerebral and Subarachnoid Hemorrhage Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.